Blue Cross and Blue Shield Association v. Jazz Pharmaceuticals, Inc. et al
Case Number:
3:20-cv-04667
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Girard Sharp
- Hagens Berman
- Kirkland & Ellis
- O'Melveny & Myers
- Skaggs Faucette
- White & Case
- Williams & Connolly
Companies
- Amneal Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- Hikma Pharmaceuticals PLC
- Jazz Pharmaceuticals Inc.
- Lupin Ltd.
- Par Pharmaceutical Cos. Inc.
Sectors & Industries:
-
December 03, 2020
Dueling Attys Call For Xyrem MDL To Be Moved To CA Or NJ
Lawyers for Blue Cross Blue Shield Association and Jazz Pharmaceuticals argued that lawsuits accusing Jazz of paying off rival drugmakers to delay their generic versions of Xyrem, its blockbuster narcolepsy drug, should be consolidated on either the West Coast or the East Coast in a Thursday hearing before the Judicial Panel on Multidistrict Litigation.
-
July 14, 2020
BCBS Says Generic Xyrem Delay Was Antitrust Scheme
Blue Cross Blue Shield Association has accused Jazz Pharmaceuticals in California federal court of paying off generic-drug makers to delay their rival versions of the pharmaceutical giant's brand name narcolepsy drug Xyrem, arguing the alleged scheme caused buyers to overpay for the drug.